Replimune Group, Inc. (REPL): Price and Financial Metrics


Replimune Group, Inc. (REPL): $18.38

0.90 (+5.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

REPL Stock Price Chart Interactive Chart >

Price chart for REPL

REPL Price/Volume Stats

Current price $18.38 52-week high $40.13
Prev. close $17.48 52-week low $13.05
Day low $17.31 Volume 214,200
Day high $18.48 Avg. volume 346,692
50-day MA $15.88 Dividend yield N/A
200-day MA $22.36 Market Cap 901.91M

Replimune Group, Inc. (REPL) Company Bio


Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.


REPL Latest News Stream


Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream


Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about Replimune Group Inc that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET.

GlobeNewswire | February 11, 2022

Replimune Group (REPL) Gets a Buy Rating from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price target of $60.00. The company's shares closed last Friday at $18.26, close to its 52-week low of $17.66. According to TipRanks.com, Burns ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.8% and a 17.9% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics. Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $52.20, implying a 188.

Christine Brown on TipRanks | February 7, 2022

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed melanoma Initial data from the ongoing study in anti-PD1 failed NMSC and from the ARTACUS trial, a Phase 1b/2 trial of RP1 as monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) RP3 initial data and the Phase 2 development plan for RP2/3 WOBURN, Mass., Feb. 03

Yahoo | February 3, 2022

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company’s Board of Directors. Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimune’s seed financing. Dr. Stampacchia has resigned to focus his efforts on his growi

Yahoo | January 31, 2022

Replimune Group (REPL) Receives a Buy from H.C. Wainwright

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price target of $60.00. The company's shares closed last Monday at $26.00, close to its 52-week low of $24.85. According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -17.7% and a 19.5% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group with a $54.

Christine Brown on TipRanks | January 11, 2022

Read More 'REPL' Stories Here

REPL Price Returns

1-mo 20.76%
3-mo 0.66%
6-mo -37.29%
1-year -53.52%
3-year 31.29%
5-year N/A
YTD -32.18%
2021 -28.96%
2020 165.85%
2019 43.50%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5532 seconds.